Detail akcie Q32 Bio Rg online

Business Summary: Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity. The Company is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7R? antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb - CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Q32 Bio Inc revenues was not reported. Net loss decreased 17% to $27.9M. Lower net loss reflects Research and development - Balancing val decrease of 59% to $15.1M (expense), General and administrative - Balancing decrease of 14% to $10.1M (expense), Loss on impairment of equity investment decrease from $1.6M (losses) to $0K.